Count

(redirected from TLC)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Idioms, Encyclopedia, Wikipedia.

Count

On a point & figure chart, an estimation of future price movements. Point & figure charts seek to identify support and resistance levels. Counts are estimates on the likelihood that a security will break through one or the other and result in a large profit or loss.
References in periodicals archive ?
Investigators at the Dana-Farber Institute/Harvard Medical School presented data from a Phase I clinical trial of a very high dose (up to 165 mg/meter squared) of TLC D-99.
TLC ABLC is in Phase II/III studies for the treatment of systemic fungal infections, TLC G-65 is in Phase II trials in the United States and Phase III in Europe for the treatment of Mycobacterium aviumintracellulare (MAI) infections in AIDS patients, TLC D-99 is in Phase II trials for treatment of metastatic breast cancer, and TLC C-53 is in Phase I trials in preparation for studies in Adult Respiratory Distress Syndrome.
Our TLC granola bar line is a great example of how easy it is to make simple changes that can have a significant impact on health and wellness.
TLC Industries is looking for selective partners for the Online Onpremise(TM) high-impact brand building opportunity.
By preventing activation of platelets, as well as neutrophils and endothelial cells, TLC C-53 may be able to both reduce reperfusion injury and prevent the no-reflow phenomenon.
NASDAQ: LIPO) today reported that a high response rate and a good safety profile have been seen with its drug TLC D-99 in a Phase II trial of patients with metastatic breast cancer.
Using Censeo's state-of-the-art assessment technology, TLC is uniquely positioned in the training marketplace by providing their pharmaceutical and biotechnology clients with a more strategic, measurement-oriented approach to learning.
TLC G-65 is a proprietary, injectable liposomal aminoglycoside antibiotic, which is currently in Phase II clinical studies for the treatment of Mycobacterium avium-intracellulare (MAI) in AIDS patients.
This refractive center performed 1800 procedures last year and has a large optometric network, which TLC will target for growth.
In addition to the potential cost savings, TLC should become a new revenue center for the company.
TLC C-53 is a liposomal prostaglandin E1 (PGE1), which is being developed as a cell adhesion antagonist.
The basic premise behind USBO's entry into the trucking market is that if USBO products are going to help growers produce commodities, then TLC trucks could help growers haul their commodities.